Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

Pharmacogenetics - 1 Oct 1997

Steward D J, Haining R L, Henne K R, Davis G, Rushmore T H, Trager W F, Rettie A E

Abstract excerpt

Cytochrome P4502C9 (CYP2C9) is largely responsible for terminating the anticoagulant effect of racemic warfarin via hydroxylation of the pharmacologically more potent S-enantiomer to inactive metabolites. Mutations in the CYP2C9 gene result in the expression of three allelic variants, CYP2C9*1, C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterozygote

Share to Homozygote

Share to Phenotype

Share to Stereoisomerism

Share to Steroid Hydroxylases

Source

Identifiers

PMID: 9352571
DOI: 10.1097/00008571-199710000-00004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-9352571-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic association between sensitivity to warfarin and expression of CYP2C9*3.PMID 9352571Read ↗

Pharmacogenetics of warfarin elimination and its clinical implications.Semantic proximity Read ↗

CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.Semantic proximity Read ↗

Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.Semantic proximity Read ↗

Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.Semantic proximity Read ↗

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.Semantic proximity Read ↗

Pharmacogenetics of oral anticoagulantsSemantic proximity Read ↗

Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.Semantic proximity Read ↗

Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.Semantic proximity Read ↗

Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.Semantic proximity Read ↗

Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.Semantic proximity Read ↗

Interindividual variability in sensitivity to warfarin--Nature or nurture?Semantic proximity Read ↗

The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.